Essential thrombocythemia with Mpl W515 K mutation in a child presenting with Budd–Chiari syndrome

References

• Jensen MK, de Nully Brown P, Nielsen OJ, Hasselbalch HC. Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. Eur J Haematol 2000;65(2):132–139
   PubMed Web of Science ®Google Scholar
• Hasle H. Incidence of essential thrombocythaemia in children. Br J Haematol 2000;110(3):751
   PubMed Web of Science ®Google Scholar
• Giona F, Teofili L, Moleti ML, Martini M, Palumbo G, Amendola A, Manzucconi MG, Testi AM, Pignoloni P, Orlando SM, Capodimonti S, Nanni M, Leone G, Larocca LM, Foa R. Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: Clinical and biologic features, treatment, and long-term outcome. Blood 2012;119(10):2219–2227
   PubMed Web of Science ®Google Scholar
• Dror Y, Blanchette VS. Essential thrombocythaemia in children. Br J Haematol 1999;107(4):691–698
   PubMed Web of Science ®Google Scholar
• Fu R, Zhang L, Yang R. Paediatric essential thrombocythaemia: Clinical and molecular features, diagnosis and treatment. Br J Haematol 2013;163(3):295–302
   PubMed Web of Science ®Google Scholar
• Tarella C, Passera R, Magni M, Benedetti F, Rossi A, Gueli A, Patti C, Parvis G, Ciceri F, Gallamini A, Cortelazzo S, Zoli V, Corradini P, Carobbio A, Mulé A, Bosa M, Barbui A, Di Nicola M, Sorio M, Caracciolo D, Gianni AM, Rambaldi A. Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: A 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol 2011;29(7):814–824
   PubMed Web of Science ®Google Scholar
• Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, Palumbo G, Amendola A, Foà R, Larocca LM. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia. J Clin Oncol 2007;25(9):1048–1053
   PubMed Web of Science ®Google Scholar
• Randi ML, Putti MC, Scapin M, Pacquola E, Tucci F, Micalizzi C, Zanesco L, Fabris F. Pediatric patients with essential thrombocythemia are mostly polyclonal and V617FJAK2 negative. Blood 2006;108(10):3600–3602
   PubMed Web of Science ®Google Scholar
• Beer PA. The pathogenesis of essential thrombocythemia. Curr Opin Hematol 2011;18(5):323–329
   PubMed Web of Science ®Google Scholar
• Farruggia P, D'Angelo P, La Rosa M, Scibetta N, Santangelo G, Lo Bello A, Duner E, Randi ML, Putti MC, Santoro A. MPL W515L mutation in pediatric essential thrombocythemia. Pediatr Blood Cancer 2013;60(8):E52–E54
   PubMed Web of Science ®Google Scholar
• Akpinar TS, Hancer VS, Nalcaci M, Diz-Kucukkaya R. MPL W515L/K mutations in chronic myeloproliferative neoplasms. Turk J Haematol 2013;30(1):8–12
   Web of Science ®Google Scholar
• Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, Wernig G, Moore S, Galinsky I, DeAngelo DJ, Clark JJ, Lee SJ, Golub TR, Wadleigh M, Gilliland DG, Levine RL. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006;3(7):e270
   PubMed Web of Science ®Google Scholar
• Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, Steensma DP, Elliott MA, Wolanskyj AP, Hogan WJ, McClure RF, Litzow MR, Gilliland DG, Tefferi A. MPL515 mutations in myeloproliferative and other myeloid disorders: A study of 1182 patients. Blood 2006;108(10):3472–3476
   PubMed Web of Science ®Google Scholar
• Solari J, Bandi JC, Galdame O, Marciano S, Mullen E, Garcia MR, Nucifora E, de Santibañes E, Gadano A. Diagnosis, treatment and evolution of the Budd–Chiari syndrome: A single center experience. Acta Gastroenterol Latinoam 2010;40(3):225–235
   PubMedGoogle Scholar
• Matsubara K, Fukaya T, Nigami H, Harigaya H, Hirata T, Nozaki H, Baba K. Age-dependent changes in the incidence and etiology of childhood thrombocytosis. Acta Haematol 2004;111(3):132–137
   PubMed Web of Science ®Google Scholar
• Chiarello P, Magnolia M, Rubino M, Liguori SA, Miniero R. Thrombocytosis in children. Minerva Pediatr 2011;63(6):507–513
   PubMedGoogle Scholar
• Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Vannucchi AM, Tefferi A. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 2012;120(26):5128–5133; quiz 252
   PubMed Web of Science ®Google Scholar
• Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22(1):14–22
   PubMed Web of Science ®Google Scholar
• Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, Palumbo G, Amendola A, Leone G, Foà R, Larocca LM. The revised WHO diagnostic criteria for Ph-negative myeloproliferative diseases are not appropriate for the diagnostic screening of childhood polycythemia vera and essential thrombocythemia. Blood 2007;110(9):3384–3386
   PubMed Web of Science ®Google Scholar
• Beer PA, Campbell PJ, Scott LM, Bench AJ, Erber WN, Bareford D, Wilkins BS, Reilly JT, Hasselbalch HC, Bowman R, Wheatley K, Buck G, Harrison CN, Green AR. MPL mutations in myeloproliferative disorders: Analysis of the PT-1 cohort. Blood 2008;112(1):141–149
   PubMed Web of Science ®Google Scholar
• Ding J, Komatsu H, Iida S, Yano H, Kusumoto S, Inagaki A, Mori F, Ri M, Ito A, Wakita A, Ishida T, Nitta M, Ueda R. The Asn505 mutation of the c-MPL gene, which causes familial essential thrombocythemia, induces autonomous homodimerization of the c-Mpl protein due to strong amino acid polarity. Blood 2009;114(15):3325–3328
   PubMed Web of Science ®Google Scholar
• Bojko P, Abenhardt W, Schnittger S, Haferlach T. Mutations in the JAK2 and MPL genes and their correlation to clinical parameters in patients with chronic myeloproliferative disease. Onkologie 2009;32(4):191–195
   PubMed Web of Science ®Google Scholar
• Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R, Kiladjian JJ, Kröger N, Mesa R, McMullin MF, Pardanani A, Passamonti F, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tefferi A; European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: Critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011;29(6):761–770
   PubMed Web of Science ®Google Scholar
• Harrison CN, Bareford D, Butt N, Campbell P, Conneally E, Drummond M, Erber W, Everington T, Green AR, Hall GW, Hunt BJ, Ludlam CA, Murrin R, Nelson-Piercy C, Radia DH, Reilly JT, Van der Walt J, Wilkins B, McMullin MF; British Committee for Standards in Haematology. Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol 2010;149(3):352–375
   PubMed Web of Science ®Google Scholar
• Horton JD, San Miguel FL, Membreno F, Wright F, Paima J, Foster P, Ortiz JA. Budd–Chiari syndrome: Illustrated review of current management. Liver Int 2008;28(4):455–466
   PubMed Web of Science ®Google Scholar
• Jantunen R, Juvonen E, Ikkala E, Oksanen K, Anttila P, Hormila P, Jansson SE, Kekomäki R, Ruutu T. Essential thrombocythemia at diagnosis: Causes of diagnostic evaluation and presence of positive diagnostic findings. Ann Hematol 1998;77(3):101–106
   PubMed Web of Science ®Google Scholar
• Yadav D, Chandra J, Sharma S, Singh V. Essential thrombocytosis and antiphospholipid antibody syndrome causing chronic Budd–Chiari syndrome. Indian J Pediatr 2012;79(4):538–540
   PubMed Web of Science ®Google Scholar
• Oo TH. Comments on “essential thrombocytosis and antiphospholipid antibody syndrome causing chronic Budd–Chiari syndrome”. Indian J Pediatr 2012;79(11):1533; author reply 4
   PubMed Web of Science ®Google Scholar
• Coban S, Ertugrul I, Ekiz F, Akif Teber M, Yuksel O. Budd–Chiari syndrome and portal vein thrombosis due to essential thrombocytosis. Platelets 2010;21(2):144–146
   PubMed Web of Science ®Google Scholar